NASDAQ:NMTR 9 Meters Biopharma (NMTR) Stock Price, News & Analysis → Pentagon contract could send this $2 AI stock soaring (From Behind the Markets) (Ad) Free NMTR Stock Alerts Add Compare Share Share Today's Range N/A50-Day Range$0.00▼$0.0252-Week Range N/AVolume76 shsAverage Volume315,915 shsMarket Capitalization$1.04 millionP/E RatioN/ADividend YieldN/APrice Target$1.70 Stock AnalysisStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesSEC FilingsSocial MediaStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesSEC FilingsSocial Media Get 9 Meters Biopharma alerts: Email Address Ad Traders Agencytop AI stock (it’s not MSFT, GOOGL, AMZN or AAPL)AI was by far the biggest tech investing trend right now. But Ross Givens says the #1 artificial intelligence stock[/lin] is NOT Microsoft, Google, Amazon or Apple. Nope — his research is pointing to a tiny, under-the-radar stock that’s trading for just a few dollars right now… And could soon shoot to the moon, handing early investors a windfall.Click here now for the full details of this stock that’s set to rocket in the AI revolution… About 9 Meters Biopharma Stock (NASDAQ:NMTR)9 Meters Biopharma, Inc., a clinical-stage biopharmaceutical company, focuses on treatments for people with rare digestive diseases, gastrointestinal conditions with unmet needs, and debilitating disorders in North America. Its lead product candidate is Vurolenatide, a long-acting injectable glucagon-like-peptide-1 that is in Phase 3 clinical trial to treat short bowel syndrome. The company is developing NM-136, a humanized monoclonal antibody for the treatment of obesity and obesity-related disorders; NM-102, a small molecule peptide to prevent antigens from trafficking into systemic circulation; and NM-003, a proprietary long-acting glucagon-like peptide-2 receptor agonist for prevention of acute graft versus host disease. Its partnered product is Larazotide, an 8-amino acid peptide, which is in Phase 2 clinical trial for treatment of multi-system inflammatory syndrome. The company has licensing agreements with Amunix, MHS Care Innovation LLC, Alba Therapeutics Corporation, and EBRIS. 9 Meters Biopharma, Inc. is headquartered in Raleigh, North Carolina. On July 17, 2023, 9 Meters Biopharma, Inc. filed a voluntary petition for liquidation under Chapter 7 in the U.S. Bankruptcy Court for the Eastern District of North Carolina.Read More Ad Traders Agencytop AI stock (it’s not MSFT, GOOGL, AMZN or AAPL)AI was by far the biggest tech investing trend right now. But Ross Givens says the #1 artificial intelligence stock[/lin] is NOT Microsoft, Google, Amazon or Apple. Nope — his research is pointing to a tiny, under-the-radar stock that’s trading for just a few dollars right now… And could soon shoot to the moon, handing early investors a windfall.Click here now for the full details of this stock that’s set to rocket in the AI revolution… NMTR Stock News HeadlinesDecember 14, 2023 | bbc.comEnergy firms likely to miss smart meter deadline, warns Which?November 8, 2023 | bizjournals.comDeal reached to sell some assets of bankrupt Raleigh firmApril 24, 2024 | Stansberry Research (Ad)The "Smart Money" Is Ready for May 1st Are You?Former Wall Street VP: "Buy This Stock Now" Five of America's Most Successful Investors Bought Shares in The Same Company. November 7, 2023 | finance.yahoo.com9 Meters Biopharma, Inc. (NMTRQ)October 17, 2023 | investing.com9 Meters Biopharma Inc (NMTRQ)August 16, 2023 | fool.com9 Meters Biopharma (OTC: NMTR.Q)July 18, 2023 | bizjournals.comRaleigh firm joins worrying trend of bankruptcies for drugmakersJuly 18, 2023 | reuters.comDrug developer 9 Meters Biopharma files for bankruptcy protectionApril 24, 2024 | Stansberry Research (Ad)The "Smart Money" Is Ready for May 1st Are You?Former Wall Street VP: "Buy This Stock Now" Five of America's Most Successful Investors Bought Shares in The Same Company. July 18, 2023 | finance.yahoo.comWhy Are 9 Meters Biopharma Shares Nosediving Today?May 30, 2023 | bizjournals.comTemperato resigns as CEO of Raleigh drugmakerMay 30, 2023 | finance.yahoo.com9 Meters Biopharma Announces Management Change and Provides Clinical Update on Vurolenatide in Patients with Short Bowel SyndromeMay 28, 2023 | fool.com9 Meters Biopharma (NASDAQ: NMTR)May 25, 2023 | uk.finance.yahoo.comNMTR - 9 Meters Biopharma, Inc.May 19, 2023 | msn.comCitigroup Maintains 9 Meters Biopharma (NMTR) Neutral RecommendationMay 15, 2023 | finance.yahoo.com9 Meters Biopharma Provides Business Update and Reports Financial Results for First Quarter 2023April 5, 2023 | finance.yahoo.com9 Meters Biopharma Announces Successful Pre-IND Meeting with FDA Regarding Its GIP Antagonist NM-136 for ObesityMarch 30, 2023 | bizjournals.comWhy this Raleigh pharma just cut half its workforceMarch 28, 2023 | finance.yahoo.com9 Meters Biopharma Provides Business Update and Reports Financial Results for Fourth Quarter and Full Year 2022March 25, 2023 | seekingalpha.comNMTR 9 Meters Biopharma, Inc.March 22, 2023 | benzinga.com9 Meters Biopharma Stock (NASDAQ:NMTR), Guidance and ForecastMarch 16, 2023 | bizjournals.comRaleigh pharma raises $5M as phase 3 study beginsMarch 15, 2023 | finance.yahoo.com9 Meters Biopharma Announces Closing of $5 Million Registered Direct Offering Priced At-The-Market Under Nasdaq RulesMarch 14, 2023 | finance.yahoo.com9 Meters Biopharma Announces $5 Million Registered Direct Offering Priced at-the-Market Under Nasdaq RulesMarch 7, 2023 | finance.yahoo.com9 Meters Biopharma to Present at the Oppenheimer 33rd Annual Healthcare ConferenceFebruary 23, 2023 | theguardian.comSuppliers told to remove prepayment meters that were wrongly force-fittedJanuary 31, 2023 | finance.yahoo.com9 Meters Biopharma to Present at the 2023 BIO CEO & Investor ConferenceSee More Headlines Receive NMTR Stock News and Ratings via Email Sign-up to receive the latest news and ratings for 9 Meters Biopharma and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings11/15/2021Today4/24/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Biotechnology Sub-IndustryN/A Current SymbolNASDAQ:NMTR CUSIPN/A CIK1551986 Webwww.9meters.com Phone(919) 275-1933FaxN/AEmployees10Year FoundedN/APrice Target and Rating Average Stock Price Target$1.70 High Stock Price Target$1.70 Low Stock Price Target$1.70 Consensus RatingHold Rating Score (0-4)2.00 Research Coverage1 Analysts Profitability EPS (Most Recent Fiscal Year)($3.46) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-43,770,000.00 Net MarginsN/A Pretax MarginN/A Return on Equity-584.97% Return on Assets-159.45% Debt Debt-to-Equity RatioN/A Current Ratio0.59 Quick Ratio0.59 Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book Value$0.19 per share Price / BookN/AMiscellaneous Outstanding Shares14,336,000Free Float13,992,000Market Cap$1.04 million OptionableNo Data Beta1.36 (Almost) Everything You Need To Know About The EV MarketClick the link below and we'll send you MarketBeat's guide to investing in electric vehicle technologies (EV) and which EV stocks show the most promise. Get This Free Report Key ExecutivesMs. Bethany Sensenig C.M.A. (Age 47)M.B.A., Interim CEO & CFO Comp: $525.59kDr. Peter H. R. Green M.D.Clinical & Scientific Advisor and ConsultantMr. Joseph A. Murray M.D.Clinical & Scientific Advisor and ConsultantDr. Ciaran P. Kelly M.D.Clinical & Scientific Advisor and ConsultantDr. Elena Verdu M.D.Ph.D., Clinical & Scientific Advisor and ConsultantMr. Markku Mäki M.D.Ph.D., Clinical & Scientific Advisor and ConsultantDr. William J. Sandborn M.D. (Age 60)Ph.D., Clinical & Scientific Advisor and Consultant Dr. Roger Liddle M.D.Clinical & Scientific Advisor and ConsultantDr. Anthony J. Dimarino Jr.Clinical & Scientific Advisor and ConsultantDr. Brian Gordon Feagan FRCPCM.D., M.P.H., Clinical & Scientific Advisor and ConsultantMore ExecutivesKey CompetitorsEiger BioPharmaceuticalsNASDAQ:EIGRBiodexa PharmaceuticalsNASDAQ:BDRXVirax Biolabs GroupNASDAQ:VRAXSmileDirectClubNASDAQ:SDCCQTC BiopharmNASDAQ:TCBPView All Competitors NMTR Stock Analysis - Frequently Asked Questions Should I buy or sell 9 Meters Biopharma stock right now? 1 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for 9 Meters Biopharma in the last twelve months. There are currently 1 hold rating for the stock. The consensus among Wall Street equities research analysts is that investors should "hold" NMTR shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in NMTR, but not buy additional shares or sell existing shares. View NMTR analyst ratings or view top-rated stocks. What is 9 Meters Biopharma's stock price target for 2024? 1 brokerages have issued 12 month price objectives for 9 Meters Biopharma's stock. Their NMTR share price targets range from $1.70 to $1.70. On average, they expect the company's share price to reach $1.70 in the next year. View analysts price targets for NMTR or view top-rated stocks among Wall Street analysts. How were 9 Meters Biopharma's earnings last quarter? 9 Meters Biopharma, Inc. (NASDAQ:NMTR) posted its quarterly earnings results on Monday, November, 15th. The company reported ($1.00) EPS for the quarter, missing analysts' consensus estimates of ($0.74) by $0.26. When did 9 Meters Biopharma's stock split? Shares of 9 Meters Biopharma reverse split before market open on Tuesday, October 18th 2022. The 1-20 reverse split was announced on Tuesday, October 18th 2022. The number of shares owned by shareholders was adjusted after the market closes on Tuesday, October 18th 2022. An investor that had 100 shares of stock prior to the reverse split would have 5 shares after the split. What other stocks do shareholders of 9 Meters Biopharma own? Based on aggregate information from My MarketBeat watchlists, some companies that other 9 Meters Biopharma investors own include Acasti Pharma (ACST), Miragen Therapeutics (MGEN), Bionano Genomics (BNGO), Evofem Biosciences (EVFM), Outlook Therapeutics (OTLK), Tonix Pharmaceuticals (TNXP), Alibaba Group (BABA), Cellectar Biosciences (CLRB), Pfizer (PFE) and Soleno Therapeutics (SLNO). How do I buy shares of 9 Meters Biopharma? Shares of NMTR stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. This page (NASDAQ:NMTR) was last updated on 4/24/2024 by MarketBeat.com Staff From Our PartnersDid You Get Your Free Bitcoin Yet?Crypto Swap Profitstop AI stock (it’s not MSFT, GOOGL, AMZN or AAPL)Traders AgencyBitcoin Rockets To Record High But Buy THIS InsteadParadigm PressDon’t Miss Out on the AI Gold Rush That’s Just Getting StartedBanyan Hill PublishingExposed: 10 CENT Crypto to Explode April 20th?True Market InsidersThe #1 Crypto for 2024InvestorPlaceFed launches fourth dollar overhaulStansberry ResearchNew Trump BombshellThe Freeport Society Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding 9 Meters Biopharma, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.